Trastuzumab
- IV infusion / SubcutTrastuzumabHerceptinInhibits ligand-independent HER signalling
- Mechanism of Action
- A monoclonal antibody directed against the HER2 receptor, which is involved in cell signalling and is overexpressed in certain cancers. Inhibition of HER2 signalling pathways results in cell cycle arrest; the monoclonal antibody also mediates antibody-dependent cell-mediated cytotoxicity.
Clinical Use
- Indications
- Contraindications
- Left ventricular dysfunction, as evidenced by an LVEF <45%, or symptomatic heart failure.
- Adverse Effects